SCHEMBL16293303

SCHEMBL16293303

CCN(CCN(C)C)C(=O)CN(Cc1cc(CO)ccn1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5B Q9UGL1 14/20 0.48
▸ KDM5C P41229 8/20 0.48
▸ KDM5A P29375 7/20 0.48
▸ KDM4A O75164 2/20 0.48
▸ KDM6B O15054 1/20 0.48
▸ KDM2B Q8NHM5 1/20 0.48
▸ KDM4C Q9H3R0 2/20 0.46
▸ KDM5D Q9BY66 1/20 0.45
▸ MEN1 O00255 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM4 P08173 1/20 0.35
▸ CHRM5 P08912 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16292660 0.85 HDAC1 (0.39) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16296605 0.85 KDM5B (0.44) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16293240 0.81 SIGMAR1 (0.38) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL15994347 0.78 KDM5B (0.73) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16292791 0.76 RECQL (0.36) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16292793 0.76 RECQL (0.36) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16293148 0.76 RECQL (0.36) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL15994238 0.76 KDM5B (0.43) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16296606 0.76 KDM5B (0.39) KDM5BKDM5CKDM5AKDM4AKDM6B
SCHEMBL16293743 0.75 LNPEP (0.38) KDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961736-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2018-04-11 — — EP disclosed
EP-3170811-A1 ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES Gilead Sciences, Inc. (US) 2017-05-24 — — EP disclosed
US-9650339-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2017-05-16 — — US disclosed
US-20160237037-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2016-08-18 — — US disclosed
US-9221801-B2 Inhibitors of histone demethylases EPITHERAPEUTICS APS (DK) 2015-12-29 — — US disclosed
US-20140371214-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371214-A1 INHIBITORS OF HISTONE DEMETHYLASES KDM1B, KDM1A, KDM3A KDM5B 27/4885KDM5C 16/4885KDM5A 21/4885
US-20160237037-A1 INHIBITORS OF HISTONE DEMETHYLASES KDM1B, KDM1A, KDM3A KDM5B 27/4885KDM5C 16/4885KDM5A 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback